Acalabrutinib Model Treated Predicted Midazolam Interaction Separately From Measured Verification

Agreement with clinical data for some interacting drugs does not make every model output a direct human observation.

What the supplied source reports

The PBPK study modeled acalabrutinib and its active metabolite. It reproduced observed parent-drug interactions with itraconazole and rifampicin reasonably well and predicted no meaningful perpetrator interaction with midazolam. Considering parent plus active metabolite altered interpretation of total active exposure.

Limits and uncertainty

The midazolam conclusion was model-based. Metabolite exposures during some interaction conditions lacked direct confirmation. The model’s assumptions and selected verification data constrain extrapolation to other populations, schedules or interacting medicines.

Implications for forensic review

For testimony, label measured verification points, simulated predictions and biological interpretation separately. A model can be useful without establishing the concentration in a specific patient. Parent-only changes may also differ from total active-drug changes, which is essential when explaining a multi-component pharmacological exposure.

Source and related reading

Source reviewed: Evaluation of the Drug Drug Interaction Potential of Acalabrutinib and Its Active Metabolite ACP 586 (PMC6656940). Forensic applications above are interpretive analysis of the supplied publication.